



منظمة الصحة العالمية



الهيئة العليا للأدوية
والمستلزمات الطبية



الجمهورية اليمنية
وزارة الصحة العامة
و السكان

القائمة الوطنية للأدوية الأساسية

الإصدار السادس

2019

بسم الله الرحمن الرحيم



كلمة وزير الصحة العامة والسكان

في السعي لتحقيق التميز في الرعاية الصحية ، والانتقاء الجيد لعدد محدود من الأدوية الأساسية يؤدي لرفع مستوى الرعاية الطبية و تحسين مستوى إدارة تأمين و توزيع الأدوية و تخفيف الهدر في الموارد الصحية و ذلك بهدف تعزيز الاستخدام الرشيد للدواء .

اختيار الأدوية الأساسية هو عملية مستمرة, كما يجري تحديثها بفترات منتظمة بحيث تؤخذ بعين الاعتبار الأولويات المتغيرة لصحة السكان وكذلك يتم اختيارها اعتمادا على انتشار المرض و القرائن المثبتة للفعالية و الأمان بالإضافة لمستجدات التطور في العلوم الدوائية .

وكما تحرص الوزارة على توفير أفضل الأدوية وأكثرها فاعلية، وتهدف الوزارة بذلك إلى أن تكون الخدمات العلاجية المُقدّمة في منشأتها المنتشرة في كافة مناطق ومحافظات اليمن من الجودة والانتساع بحيث تغطي كل الأمراض وتكون سبباً في الشفاء منها بإذن الله.

وبناء عليه أدعو الجميع في القطاعات الصحية المختلفة بالالتزام بقائمة الأدوية الأساسية الوطنية.

وفي الاخير أتقدم بجزيل الشكر لكل من ساهم في إعداد وإخراج قائمة الأدوية الأساسية الوطنية الإصدار السادس وأخص بالذكر كافة أعضاء اللجنة العلمية متطلعاً لمزيد من البذل والعطاء في سبيل خدمة وطننا العزيز .

الشفاء للجرحى
الخلود للشهداء
النصر لجيشنا البواسل ولجاننا الشعبية

أ.د.إله أحمد المتوكّل
وزير الصحة العامة والسكان



بسم الله الرحمن الرحيم

كلمة رئيس الهيئة

الحمد لله رب العالمين والشكر لله على توفيقه والصلاة والسلام على سيد المرسلين محمد صلوات الله عليه وعلى آله وسلم.

يأتي اعداد وانجاز القائمة الوطنية للأدوية الأساسية الاصدار السادس في إطار توجيهات وزير الصحة العامة والسكان أ. د طه أحمد المتوكل وسعي الهيئة العليا للأدوية والمستلزمات الطبية الى رسم سياسة دوائية وطنية تتناسب مع حاجة المجتمع من أجل انتقاء وتوفير الادوية الآمنة والفعالة وذات التكلفة المناسبة.

اننا في الهيئة العليا للأدوية سنحرص من خلال الدعم والمتابعة لضمان توفير واعتماد وصف الأدوية الواردة في هذه القائمة الوطنية وكذلك من خلال التركيز على تشجيع الصناعات الدوائية المحلية من أجل توفير كل ما تتضمنه القائمة من الأدوية الأساسية بما يؤدي الى رفع نسبة مساهمة الصناعة الوطنية لها وتشجيع الاكتفاء الذاتي الدوائي وكسر الحصار الجائر للدواء المفروض على بلدنا من قبل دول العدوان.

ومن أجل التقليل من حجم الانفاق الدوائي على الفرد والدولة والحد من عشوائية صرف وتناول الادوية فإننا ندعوا جميع شركات ومصنعي الأدوية وجميع منتسبي المهن الطبية والمؤسسات الصحية الى الأخذ بعين الاعتبار والالتزام بما ورد في القائمة الأساسية من أجل توفير وترشيد استخدام الدواء وتحقيق المنفعة المرجوة منها بعون الله وان يوافقنا بأي ملاحظات او مقترحات ستساعد على مراجعة وتطوير قائمة الادوية الأساسية، وستسعى الهيئة بأن يتم تحديث هذه القائمة بشكل مستمر ودوري من أجل مواكبة التحديثات الدوائية والمتغيرات الصحية والطارئة بما يضمن تلبية احتياجات البلد.

وفي الاخير اتقدم بجزيل الشكر والتقدير لكل من دعم وساهم في إعداد وصياغة وإخراج هذه القائمة الوطنية للأدوية الأساسية الاصدار السادس وخصوصاً أعضاء اللجنة العلمية متطلعاً لمزيد من البذل والعطاء في سبيل خدمة وطننا الغالي.

الرحمة للشهداء

الشفاء للجرحى

الحرية للأسرى

النصر لجيشنا البواسل ولجاننا الشعبية

د/محمد يحيى المداني

رئيس الهيئة العليا للأدوية والمستلزمات
الطبية

Introduction

Under the supervision of the Minister of Public Health Prof. TAHA AL-MOTAWAKEL, the Preparation for Updating the National Essential Medicines List of Yemen was arranged by the Supreme board of Drugs and Medical Appliances (SBDMA) in collaboration with the National program for drug supply (NPDS) and World Health Organization (WHO) support. During our preparation of Essential Medicines List of Yemen we have do workshop was held on 26th and -27th of December, 2018 in Taj Sheba Hotel, Sana'a, Yemen. The objectives of the workshop were to involve the practicing physicians, pharmacists, health program leaders, and key decision makers in revising the previous essential medicines list of the country that was constructed in 2014. The workshop highlighted the WHO criteria to the participants in order to make the process of updating the national list valid, beneficial, and relevant to the populations. At the workshop days On first day of the workshop, the aim and the process of the workshop were reemphasized to the participants. Then, they assembled in related clusters. Finally, at second day, clusters present their recommendations. Each presentation was followed by rigorous discussion. These recommendations were collected, analyzed, and summarized by the workshop facilitators. Ultimately, facilitators drafted the sixth National EML of Yemen. The Yemen's National Essential Medicines List (NEML) presents a list of at least one option for the single health care need and based on the 20th List Model List of Essential Medicines of the WHO and Yemen's National Essential Medicines List (NEML) 2014. The selection of the list was based on priority health needs, medicines efficacy, safety, suitability and cost-effectiveness. The NEML Medicines list will be updated every two years; however, any proposal for addition/deletion is mostly welcomed during this period and will be discussed by the National Drug and Therapeutics Committee. The symbol indicates that there is an age or weight restriction on use of the medicine Where The square box symbol (□) is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources. Not all square boxes are applicable to medicine selection for children. The (A) symbol indicates that there is an age or weight restriction on use of the medicine; details for each medicine can be found in Table 1.1.

اللجنة الإشرافية

رئيساً	أ.د / طه المتوكل
نائباً	د / محمد يحيى المداني
أ.د / عبدالله الدهلي	أ.د / محمد الكبسي
عضواً	عضواً
د / سمير السنافي	د / فايز خالد سكران
عضواً	عضواً
د / محمد الغيلي	د / يوسف الحاضري
عضواً	عضواً

الأسماء المشاركة في إعداد القائمة الوطنية للأدوية الأساسية

د ناصر يحيى علي الغريب	د. نجيب عبدالله سيف
أ.د عبدالله عبدالوهاب الشرعبي	أ.د. يحيى علي غاتم
د. صابر حزام صالح القحيف	د. محمد علي عبد المجيد النزيلي
د. محمد حسن نصار	د. طه احمد العقاري
أ.د نورة علي نور الدين	د غمدان رزق الجوفي
د سماح محمد لطف العطاب	د. عبدالغني محمد سعد الفضل
د عبد الله محمد هادي مجلي	د. شمسان علي محسن قدام
أ.د فيصل محمد البابلي	د عبد الفتاح محمد المهدي
أ.د نجيب وازع ابو إصبع	د. رضوان عبدالرحمن ناجي القدسي
د/أحمد عبدالملك شرف الدين	د امين قاسم رزق
د محمد علي أحمد الغنسي	د صالح مسعد محمد الحفظاني
أ.د مطيع عبدالله ابو عريج	أ.د عبدالكريم محمد ثامر
د محمد الغوري	د. مطهر عباس المروني
د ابراهيم يحيى ابوطالب	أ.د مجاهد علي معصار
د عبدالعزیز يحيى الديلمي	د. عبدالله حسن ثابت
د نـاظم الحـاج	أ.د امين عبدالرب
د نجيب خليل القباطي	أ.د سمير عبدالرحمن ثابت
د/أنور محمد عبدالله جحاف	د عادل محمد الحضرمي
د/ خالد عبدالله المؤيد	د/ منصور عبدالله غالب
د/ بشري عبدالجليل	د/ محمد عبدالله عاطف
د/عبدالقوي علي الجنيد	د/ محمد عبدالله الدويلة
د/علي عبدالوهاب المفتي	د/محمود مهيوب البريهي

The Yemeni National Essential Medicines List, Version 6, 2019

Levels of Health Facilities							
Facility Type	Health Unit	Health Center	District Hospital	Inter-District Hospital	General Hospital	Governorate Hospital	Referral Hospital
Facility Level	1	2	3	4	5	6	7

Medicine Class and Generic Name	Dosage Form and Strength	Classification VEN System	Health Facility Level
1. ANAESTHETICS, PREOPERATIVE MEDICINES AND MEDICAL GASES			
1.1 General anesthetics and medical Gases			
1.1.1 Inhalational medicines			
halothane	Inhalation (in 250 mL bottle).	V	3
isoflurane	Inhalation (in 250 mL bottle).	V	3
nitrous oxide	Inhalation in cylinder.	V	3
oxygen	Inhalation (medical gas in cylinder).	V	3
1.1.1.2 Powder medicines			
thiopental sodium	Powder for injection: 1 g vial.	V	3
1.1.2 Injectable medicines			
ketamine	Injection: 50 mg (as hydrochloride)/ mL in 10- mL vial.	V	3
propofol	Injection: 10 mg/ mL; 20 mg/ mL.	V	3
1.2 Local anesthetics			
☐ bupivacaine	Injection: 0.25%; 0.5% (hydrochloride) in vial.	E	3
	Injection for spinal anaesthesia: 0.5% (hydrochloride) in 4- mL ampoule to be mixed with 7.5% glucose solution.	E	3

□ lidocaine	Injection: 1%; 2% (hydrochloride) in vial.	E	1
	Injection for spinal anaesthesia: 5% (hydrochloride) in 2- mL ampoule.	E	3
	Topical forms: 2% to 4% (hydrochloride).	N	3
lidocaine + epinephrine (adrenaline)	Dental cartridge: 2% (hydrochloride) + epinephrine 1:80000.	E	2
	Injection: 1%; 2% (hydrochloride or sulfate) + epinephrine 1:200 000 in vial.	E	3
1.3 Preoperative medication and sedation for short-term procedures			
atropine	Injection: 1 mg (sulfate) in 1- mL ampoule.	V	2
□ midazolam	Injection: 1 mg/ mL.	V	3
diazepam	Injection: 5 mg/mL (in 2- mL ampoule.	V	3
morphine	Injection: 10 mg (sulfate or hydrochloride) in 1- mL ampoule.	E	3
		E	3
2. MEDICINES FOR PAIN AND PALLIATIVE CARE			
2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)			
acetylsalicylic acid	Tablet: 300 mg to 500 mg.	E	1
ibuprofen	Oral liquid: 200 mg/5 mL.	E	2
	Tablet: 200 mg; 400 mg; 600 mg.	E	
paracetamol	Oral liquid: 120 mg/5 mL in 60 mL bottle.	E	1
	Suppository: 120 mg.	E	1
	Tablet: 500 mg.	E	1
	Injection: 1g/100 mL solution for infusion vials.	E	3
diclofenac sodium	Injection: 25mg/mL in 3 mL ampule.	N	
2.2 Opioid analgesics			
fentanyl	Transdermal patch: 50 micrograms/hr; 75 micrograms/hr; 100 micrograms/hr.	V	3
□ morphine	Granules (slow-release; to mix with water): 20 mg –200 mg (morphine sulfate).		7
	Injection: 10 mg (morphine hydrochloride or morphine sulfate) in 1- mL ampoule.	E	3
	Oral liquid: 10 mg (morphine hydrochloride or morphine sulfate)/5 mL.	E	7
	Tablet (slow release): 10 mg–200mg (morphine hydrochlorideor morphine .(sulfate	E	7
	Tablet (immediate release): 10 mg	E	7

	(morphine sulfate).		
methadone	Tablet: 5 mg; 10 mg (as hydrochloride)	E	7
	Oral liquid: 5mg/ 5mL; 10mg/ 5mL (as hydrochloride)	E	7
	Concentrate for oral liquid: 5 mg/ mL; 10mg/ mL (as hydrochloride)	E	7
2.3 Medicines for other common symptoms in palliative care			
amitriptyline	Tablet: 25 mg; 50 mg.	V	
diazepam	Injection: 5 mg/ mL.		
	Oral liquid: 2 mg/5 mL.		
	Rectal solution: 2.5 mg; 5 mg; 10 mg.		
	Tablet: 5 mg; 10 mg.		
hyoscine butyl bromide	Injection: 20 mg/ mL.		
lactulose	Oral liquid: 3.1–3.7 g/5 mL.		2
loperamide	Solid oral dosage form: 2 mg.		
3. ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS			
Chlorpheniramine	Injection: 10 mg / mL in 1- mL ampoule	E	2
	Solid oral dosage form: Eq 4 mg	E	1
dexamethasone	Injection: 4 mg/ mL in 1- mL ampoule (as disodium phosphate salt).		
epinephrine (adrenaline)	Injection: 1 mg (as hydrochloride or hydrogen tartrate) in 1- mL ampoule.	V	2
hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial.	V	2
□ loratadine	Oral liquid: 1 mg/ mL.	E	2
	Tablet: 10 mg.	E	2
□ prednisolone	Oral liquid: 5 mg/ mL.	E	2
	Tablet: 5 mg; 20 mg.	E	2
4. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS			
4.1 Non-specific			
charcoal, activated	Powder.	V	1
4.2 Specific			
acetylcysteine	Injection: 200 mg/ mL in 10- mL ampoule.		
atropine	Injection: 1 mg (sulfate) in 1- mL ampoule.	V	2
calcium gluconate	Injection: 100 mg/ mL in 10- mL ampoule.	V	6
methylthion	Injection: 10 mg/ mL in 10- mL ampoule.	V	3

nium chloride (methylene blue)			
naloxone	Injection: 400 micrograms (hydrochloride) in 1- mL ampoule.	V	3
penicillamine	Solid oral dosage form: 250 mg.	V	3
sodium nitrite	Injection: 30 mg/ mL in 10- mL ampoule.	V	3
sodium thiosulfate	Injection: 250 mg/ mL in 50- mL ampoule.	V	6
Neostigmine Methylsulphate	Injection: 2.5mg/mL, amp. 10ml	V	3
Pralidoxime Mesilate	Injection: 200 mg/ mL in 5- mL ampoule	V	3
Protamine Sulphate	Injection: 10 mg/ mL in 5- mL ampoule	V	5
Phytomenadione (Vit. K1)	Injection: 10mg/mL , amp 1ml	V	3
Dantrolene	Injection: 20mg/vial , powder	V	3
deferoxamine mesilate	Powder for injection: 500 mg (mesilate) in vial.	V	3
flumazenil	Injection: 100 mcg/mL, amp. 5 mL	V	
benzotropine	Tablet (scored): 1 mg.	V	3
sodium calcium edetate	Injection: 200 mg/ mL in 5- mL ampoule.	V	3
5. ANTICONVULSANTS/ANTIEPILEPTICS			
carbamazepine	Oral liquid: 100 mg/5 mL.	V	3
	Tablet (chewable): 100 mg; 200 mg.	V	3
	Tablet (scored): 200 mg.	V	3
clonazepam	Oral liquid: 2.5 mg/1 mL.	E	3
	Tablet (scored): 2 mg.	E	2
diazepam	Gel or rectal solution: 5 mg/ mL in 0.5 mL; 2- mL; 4- mL tubes.	V	2
lamotrigine	Tablet: 25 mg; 50 mg; 100 mg; 200 mg.	E	2
□ lorazepam	Parenteral formulation: 2 mg/ mL in 1- mL ampoule; 4 mg/ mL in 1- mL ampoule.	E	2
magnesium sulfate	Injection: 0.5g/ mL in 2- mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume); 0.5g/ mL in 10- mL ampoule (equivalent to 5 g in 10 mL; 50%	E	2

	weight/volume).		
phenobarbital	Oral liquid: 15 mg/5 mL.	V	2
	Tablet: 60 mg.	V	2
phenytoin	Injection: 50 mg/ mL in 5- mL vial (sodium salt).	V	2
	Oral liquid: 25 mg to 30 mg/5 mL.	V	2
	Solid oral dosage form: 25 mg; 50 mg; 100 mg (sodium salt).	V	2
valproic acid (sodium valproate)	Oral liquid: 200 mg/5 mL.	E	2
	Tablet (enteric-coated): 200 mg; 500 mg (sodium valproate).	E	2
6. ANTI-INFECTIVE MEDICINES			
6.1 Anthelmintics			
6.1.1 Intestinal anthelmintics			
albendazole	Tablet (chewable): 400 mg, suspension 100 mg/5 mL in 20 mL & 30 mL bottle.	E	1
	Suspension: 100 mg/5 mL in 20 mL & 30 mL .bottle		
ivermectin	Tablet (scored): 3 mg.		
mebendazole	Tablet (chewable): 100 mg & 500 mg; oral suspension 100 mg/5 mL in 30 mL bottle.	E	1
niclosamide	Tablet (chewable): 500 mg.		
praziquantel	Tablet: 150 mg; 600 mg.	V	1
pyrantel (as embonate)	Tablet (chewable): 250 mg.	E	1
	Oral liquid: 50 mg/mL.	E	1
6.1.2 Antifilarials			
ivermectin	Tablet (scored): 3 mg.	E	1
albendazole	Tablet (chewable): 400 mg, suspension 100 mg/5 mL in 20 mL & 30 mL bottle.	E	1
6.1.3 Antischistosomes and other antitrepanematode medicines			
praziquantel	Tablet: 500 mg & 600 mg.	V	1
6.2 Antibacterials			
6.2.1 Beta-lactam medicines			
amoxicillin	Oral liquid: 125 mg (as trihydrate)/5 mL; 250 mg (as trihydrate)/5 mL.	V	1
	Solid oral dosage form: 250 mg; 500 mg (as trihydrate).	V	1
	Powder for injection: 250 mg; 500 mg; 1 g (as sodium) in vial.	V	2
amoxicillin + clavulanic	Oral liquid: 125 mg amoxicillin + 31.25 mg clavulanic acid/5 mL AND 250 mg	V	1

acid	amoxicillin + 62.5 mg clavulanic acid/5 mL.		
	Tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt).	V	1
	Powder for injection: 500 mg (as sodium) + 100 mg (as potassium salt); 1000 mg (as sodium) + 200 mg (as potassium salt) in vial.	V	2
ampicillin	Powder for injection: 500 mg & 1000 mg in 5- mL vial.	E	2
benzathine benzylpenicillin	Powder for injection: 900 mg benzylpenicillin (= 1.2 million IU) in 5- mL vial; 1.44 g benzylpenicillin (= 2.4 million IU) in 5- mL vial.	V	3
benzylpenicillin	Powder for injection: 600 mg (= 1 million IU); 3 g (= 5 million IU) (sodium or potassium salt) in vial.	N	3
cefazolin	Powder for injection: 1 g (as sodium salt) in vial.	E	3
cefuroxime	Tablet (as axetil): 500 mg.	E	3
	Suspension (as axetil): 250 mg/5mL in 100 mL bottle.	E	3
	Injection: 1.5 g/50 mL.	V	3
cefixime	Capsule or tablet: 200 mg; 400 mg (as trihydrate).	E	3
	Powder for oral liquid: 100 mg /5 mL.	E	3
cefotaxime	Powder for injection: 250 mg per vial (as sodium salt).	N	3
ceftriaxone	Powder for injection: 250 mg; 1 g (as sodium salt) in vial.	N	2
☐ cloxacillin	Capsule: 500 mg; 1 g (as sodium salt).	N	3
	Powder for injection: 500 mg (as sodium salt) in vial.	E	3
	Powder for oral liquid: 125 mg (as sodium salt)/5 mL.	E	4
ceftazidime	Powder for injection: 250 mg or 1 g (as pentahydrate) in vial.	E	4
procaine benzylpenicillin	Powder for injection: 1 g (=1 million IU); 3 g (=3 million IU) in vial.	E	4
6.2.2 Other antibacterials			

amikacin	Injection: 250 mg (as sulfate)/mL in 2- mL vial	V	7
azithromycin	Capsule: 250 mg; 500 mg (anhydrous).	E	5
	Oral liquid: 200 mg/5 mL.	E	5
ciprofloxacin	Solution for IV infusion: 2 mg/ mL (as hyclate). Tablet (scored): 500 mg (as hydrochloride).	E	2
clarithromycin	Solid oral dosage form: 500 mg.	N	2
	Powder for injection: 500 mg in vial.	N	2
clindamycin	Capsule: 150 mg (as hydrochloride).	N	3
	Injection: 150 mg (as phosphate)/ mL.	N	3
	Oral liquid: 75 mg/5 mL (as palmitate).	N	3
doxycycline	Oral liquid: 25 mg/5 mL; 50 mg/5 mL (anhydrous).	N	3
	Solid oral dosage form: 50 mg; 100 mg (as hyclate).		
	Powder for injection: 100 mg in vial.		
gentamicin	Injection: 10 mg; 40 mg (as sulfate)/ mL in 2- mL vial.	E	5
metronidazole	Injection: 500 mg in 100- mL vial.	E	5
	Oral liquid: 200 mg (as benzoate)/5 mL.	E	1
	Suppository: 500 mg; 1 g.	E	3
	Tablet: 200 mg to 500 mg.	E	1
nitrofurantoin	Oral liquid: 25 mg/5 mL.	N	3
	Tablet: 100 mg.	N	3
sulfamethoxazole + trimethoprim	Injection: 80 mg + 16 mg/ mL in 5- mL ampoule; 80 mg + 16 mg/ mL in 10- mL ampoule.	V	1
	Oral liquid: 200 mg + 40 mg/5 mL.	V	1
	Tablet: 100 mg + 20 mg; 400 mg + 80 mg; 800 mg + 160 mg.	V	1
vancomycin	Powder for injection: 250 mg (as hydrochloride) in vial.	V	3
6.2.3 Antileprosy medicines			
clofazimine	Capsule: 50 mg; 100 mg.	E	2
dapsone	Tablet: 25 mg; 50 mg; 100 mg.	E	2
Rifampicin	Solid oral dosage form: 150 mg; 300 mg.	V	2
6.2.4 Antituberculosis medicines			

ethambutol	Tablet: 400 mg (hydrochloride).	V	3
ethambutol + isoniazid + pyrazinamide + rifampicin	Tablet: 275 mg + 75 mg + 400 mg + 150 mg.	V	3
ethambutol + isoniazid + rifampicin	Tablet: 275 mg + 75 mg + 150 mg.	E	3
isoniazid	Tablet: 100 mg to 300 mg.	V	3
isoniazid + pyrazinamide + rifampicin	Tablet (dispersible): 50 mg + 150 mg + 75 mg.	V	3
isoniazid + rifampicin	Tablet: 75 mg + 150 mg; 150 mg + 300 mg.	V	3
pyrazinamide	Tablet: 400 mg.	V	3
Levofloxacin	Tablet: 250,500mg	N	3
amikacin	Powder for injection: 100 mg; 500 mg; 1 g (as sulfate) in vial.	N	3
capreomycin	Powder for injection: 1 g (as sulfate) in vial.	N	3
cycloserine	Solid oral dosage form: 250 mg.	N	3
ethionamide	Tablet: 250 mg.	N	3
p-aminosalicylic acid	Granules: 4 g in sachet.	E	3
	Tablet: 500 mg.	E	3
streptomycin	Powder for injection: 1 g (as sulfate) in vial.	E	3
6.3 Antifungal medicines			
amphotericin B	Powder for injection: 50 mg in vial (as sodium deoxycholate or liposomal complex).	N	1
clotrimazole	Vaginal cream: 1%; 10%.	E	2
	Vaginal tablet: 100 mg; 500 mg.	E	2
fluconazole	Capsule: 50 mg.	E	2
	Injection: 2 mg/ mL in vial.	E	1
	Oral liquid: 50 mg/5 mL.	E	1
griseofulvin	Oral liquid: 125 mg/5 mL.	E	1
	Solid oral dosage form: 125 mg; 250 mg.	E	4
itraconazole	Capsule: 100 mg.	E	3
	Oral liquid: 10 mg/mL.	E	3
Nystatin	Oral liquid: 50 mg/5 mL; 100 000 IU/ mL.	E	3
	Pessary: 100 000 IU.		
6.4 Antiviral medicines			
6.4.1 Antiherpes medicines			

❑ aciclovir	Oral liquid: 200 mg/5 mL.	V	3
	Powder for injection: 250 mg (as sodium salt) in vial.	V	3
	Tablet: 200 mg.	V	3
6.4.2 Antiretrovirals			
6.4.2.1 Nucleoside/Nucleotide reverse transcriptase inhibitors			
abacavir (ABC)	Tablet: 300 mg (as sulfate).	E	3
	Tablet (dispersible, scored): 60 mg (as sulfate).	E	3
lamivudine (3TC)	Oral liquid: 50 mg/5 mL.	E	3
	Tablet: 150 mg.	E	3
tenofovir disoproxil fumarate (TDF)	Tablet: 300 mg (tenofovir disoproxil fumarate – equivalent to 245 mg tenofovir disoproxil).	V	3
zidovudine (ZDV or AZT)	Capsule: 250 mg.	V	3
	Oral liquid: 50 mg/5 mL.	V	3
	Solution for IV infusion injection: 10 mg/mL in 20- mL vial.	V	3
	Tablet: 300 mg.	V	3
	Tablet (dispersible, scored): 60 mg (as sulfate).	V	3
6.4.2.2 Non-nucleoside reverse transcriptase inhibitors			
efavirenz (EFV or EFZ)	Tablet: 200 mg (scored); 600 mg.	E	4
		E	4
nevirapine (NVP)	Oral liquid: 50 mg/5 mL.	E	4
	Tablet: 50 mg (dispersible); 200 mg.	E	4
6.4.2.3 Protease inhibitors			
atazanavir + ritonavir	Tablet (heat stable): 300 mg (as sulfate) + 100 mg.	V	5
FIXED-DOSE COMBINATIONS			
abacavir + lamivudine	Tablet (dispersible, scored): 60 mg (as sulfate) + 30 mg; 120 mg (as sulfate) + 60 mg.	E	4

efavirenz + emtricitabine + tenofovir	Tablet: 600 mg + 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil).	E	4
efavirenz + lamivudine + tenofovir	Tablet: 400 mg + 300 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	E	4
emtricitabine + tenofovir	Tablet: 200 mg + 300 mg (disoproxil fumarate equivalent to 245 mg tenofovir disoproxil).	E	4
lamivudine + nevirapine + zidovudine	Tablet: 30 mg + 50 mg + 60 mg; 150 mg + 200 mg + 300 mg.	E	4
lamivudine + zidovudine	Tablet: 30 mg + 60 mg; 150 mg + 300 mg.	E	4
6.4.2.5 Medicines for prevention of HIV-related opportunistic infections			
isoniazid + pyridoxine + sulfamethoxazole + trimethoprim	Tablet (scored): 300 mg + 25 mg + 800 mg + 160 mg.	V	3
6.4.3 Other antivirals			
ribavirin	Injection for intravenous administration: 800 mg and 1 g in 10- mL phosphate buffer solution.	E	4
	Solid oral dosage form: 200 mg; 400 mg; 600 mg.	E	4
valganciclovir	Tablet: 450 mg.	E	4
oseltamivir	Capsule: 30 mg; 45 mg; 75 mg (as phosphate).	E	4
	Oral powder: 12 mg/ mL.	E	4
6.4.4 Antihepatitis medicines			
6.4.4.1 Medicines for hepatitis B			
6.4.4.1.1 Nucleoside/Nucleotide reverse transcriptase inhibitors			
entecavir	Oral liquid: 0.05 mg/ mL	E	4
	Tablet: 0.5 mg; 1 mg	E	4
tenofovir disoproxil fumarate (TDF)	Tablet: 300 mg (tenofovir disoproxil fumarate – equivalent to 245 mg tenofovir disoproxil).	E	4
6.4.4.2 Medicines for hepatitis C			

FIXED-DOSE COMBINATIONS			
ledipasvir + sofosbuvir	Tablet: 90 mg + 400 mg.	E	3
sofosbuvir + velpatasvir	Tablet: 400 mg + 100 mg	E	3
sofosbuvir + ribavirine	Tablet: 400 mg + 200 mg.	N	3
6.5 Antiprotozoal medicines			
6.5.1 Antiamoebic and anti giardiasis medicines			
diloxanide	Tablet: 500 mg (furoate).	E	3
□ metronidazole	Injection: 500 mg in 100- mL vial.	E	2
	Oral liquid: 200 mg (as benzoate)/5 mL.	E	1
	Tablet: 200 mg to 500 mg.	E	1
6.5.2 Antileishmaniasis medicines			
amphotericin B	Powder for injection: 50 mg in vial (as sodium deoxycholate or liposomal complex).	V	2
paromomycin	Solution for intramuscular injection: 750 mg of paromomycin base (as the sulfate).	V	2
sodium stibogluconate	Injection: 100 mg/ mL, 1 vial = 30 mL or 30%, equivalent to approximately 8.1% antimony (pentavalent) in 5- mL ampoule.	V	2
6.5.3 Antimalarial medicines			
6.5.3.1 For curative treatment			
artemether	Oily injection: 80 mg/ mL in 1- mL ampoule.	V	2
artemether + lumefantrine	Tablet: 20 mg + 120 mg.	V	2
	480mg+120mg	V	2
	360mg+80mg	V	2
	240mg+40mg	V	2
	120mg+20mg	V	2
artesunate	Injection: ampoules, containing 60 mg anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution.	V	2
	Suppositories: 50mg	V	2
chloroquine	Oral liquid: 50 mg (as phosphate or sulfate)/5 mL.	V	2

	Tablet: 100 mg; 150 mg (as phosphate or sulfate).	V	2
quinine	Injection: 300 mg quinine hydrochloride/ mL in 2- mL ampoule.	V	2
	Tablet: 300 mg (quinine sulfate) or 300 mg (quinine bisulfate).	V	2
mefloquine	Tablet: 250 mg (as hydrochloride).	V	2
primaquine	Tablet: 7.5 mg; 15 mg (as diphosphate).	V	2
sulfadoxine + pyrimethamine+artesunate	Tablet: 50 mg + 500 mg+25mg	V	1
	100mg+500mg+25mg	V	1
6.5.3.2 For prophylaxis			
doxycycline	Solid oral dosage form: 100 mg (as hydrochloride or hyclate).	V	1
mefloquine	Tablet: 250 mg (as hydrochloride).	V	1
proguanil	Tablet: 100 mg (as hydrochloride).	V	1
6.5.4 Antipneumocystosis and antitoxoplasmosis medicines			
pyrimethamine	Tablet: 25 mg.	E	2
sulfamethoxazole + trimethoprim	Injection: 80 mg + 16 mg/ mL in 5- mL ampoule; 80 mg + 16 mg/ mL in 10- mL ampoule.	V	2
	Oral liquid: 200 mg + 40 mg/5 mL.	V	1
	Tablet: 100 mg + 20 mg; 400 mg + 80 mg.	V	1
pentamidine	Tablet: 200 mg; 300 mg (as isethionate).		
7. ANTIMIGRAINE MEDICINES			
7.1 For treatment of acute attack			
ibuprofen	Tablet: 200 mg; 400 mg.	N	2
paracetamol	Oral liquid: 120 mg/5 mL; 125 mg/5 mL.	E	1
	Tablet: 300 mg to 500 mg.	E	1
Sumatriptan	Tablet: 50 mg.	N	2
7.2 For prophylaxis			
☐ propranolol	Tablet: 20 mg; 40 mg (hydrochloride).	V	2
8. ANTINEOPLASTICS AND IMMUNOSUPPRESSIVES			

8.1 Immunosuppressive medicines			
ciclosporin	Capsule: 25 mg, 50 mg, 100 mg.	V	7
	Concentrate for injection: 50 mg/ mL in 1-mL ampoule for organ transplantation.	V	7
mycophenolate	Capsule: 500 mg.	V	7
azathioprine	.Tablet (scored): 50 mg	V	7
Sirolimus	Capsule: 1 mg.	V	7
Tacrolimus	Capsule: 1 mg. ; 0.5 mg	V	7
8.2 Cytotoxic and adjuvant medicines			7
asparaginase	Powder for injection: 10 000 IU in vial.	V	7
bleomycin	Powder for injection: 15 mg (as sulfate) in vial.	V	7
calcium folinate	Injection: 3 mg/ mL in 10- mL ampoule; 5mg/ mL in 10- mL ampoule.	V	7
	Tablet: 15 mg.	V	7
capecitabine	Tablet: 150 mg; 500 mg.	V	7
carboplatin	Injection: 50 mg/5 mL; 150 mg/15 mL; 450 mg/45 mL; 600 mg/60 mL.	V	7
chlorambucil	Tablet: 2 mg.	V	7
cisplatin	Injection: 50 mg/50 mL; 100 mg/100 mL.	V	7
cyclophosphamide	Powder for injection: 500 mg in vial.	V	7
	Tablet: 25 mg.	V	7
cytarabine	Powder for injection: 1000 mg in vial.	V	7
dacarbazine	Powder for injection: 100 mg in vial.	V	7
dactinomycin	Powder for injection: 500 micrograms in vial.	V	7
dasatinib	Tablet: 20 mg; 50 mg; 70 mg; 80 mg; 100 mg; 140 mg.	V	7
daunorubicin	Powder for injection: 50 mg (hydrochloride) in vial.	V	7
docetaxel	Injection: 20 mg/ mL; 40 mg/ mL.	V	7
doxorubicin	Powder for injection: 10 mg; 50 mg (hydrochloride) in vial.	V	7

etoposide	Capsule: 100 mg.	V	7
	Injection: 20 mg/ mL in 5- mL ampoule.	V	7
filgrastim	Injection: 120 micrograms/0.2 mL; 300 micrograms/0.5 mL; 480 micrograms/0.8 mL in pre-filled syringe 300 micrograms/mL in 1- mL vial, 480 mg/1.6 mL in 1.6- mL vial.	V	7
fludarabine	Powder for injection: 50 mg (phosphate) in vial.	V	7
	Tablet: 10 mg.	V	7
fluorouracil	Injection: 50 mg/ mL in 5- mL ampoule.	V	7
gemcitabine	Powder for injection: 200 mg in vial, 1 g in vial.	V	7
hydroxycarbamide	Solid oral dosage form: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g.	V	7
melphalan	2 mg	V	7
Hydroxyurea	Capsules: 500mg	V	7
ifosfamide	Powder for injection: 500 mg vial; 1-g vial; 2-g vial.	V	7
imatinib	Tablet: 100 mg; 400 mg.	V	7
irinotecan	Injection: 40 mg/2 mL in 2- mL vial; 100 mg/5 mL in 5- mL vial; 500 mg/25 mL in 25- mL vial.	V	7
mercaptopurine	Tablet: 50 mg.	V	7
mesna	Injection: 100 mg/ mL in 4- mL and 10- mL ampoules.	V	7
	Tablet: 400 mg; 600 mg.	V	7
methotrexate	Powder for injection: 50 mg (as sodium salt) in vial.	V	7
	Tablet: 2.5 mg (as sodium salt).	V	7
nilotinib	Capsule: 150 mg; 200 mg.	V	7
oxaliplatin	Injection: 50 mg/10 mL in 10- mL vial; 100 mg/20 mL in 20- mL vial; 200 mg/40 mL in 40- mL vial.	V	7
	Powder for injection: 50 mg, 100 mg in vial.	V	7
paclitaxel	Powder for injection: 6 mg/ mL.	V	7

procarbazine	Capsule: 50 mg (as hydrochloride).	V	7
rituximab	Injection: 100 mg/10 mL in 10- mL vial; 500 mg/50 mL in 50- mL vial.	V	7
trastuzumab	Powder for injection: 60 mg; 150 mg; 440 mg in vial.	V	7
vinblastine	Powder for injection: 10 mg (sulfate) in vial.	V	7
vincristine	Powder for injection: 1 mg; 5 mg (sulfate) in vial.	V	7
vinorelbine	Injection: 10 mg/mL in 1- mL vial; 50 mg/5 mL in 5- mL vial.	V	7
zoledronic acid	Concentrate solution for infusion: 4 mg/5 mL in 5- mL vial.	V	7
	Solution for infusion: 4 mg/100 mL in 100- mL bottle.	V	7
8.3 Hormones and antihormones			
☐ anastrozole	Tablet: 1 mg.	E	
☐ bicalutamide	Tablet: 50 mg.	E	4
dexamethasone	Injection: 4 mg/ mL in 1- mL ampoule (as disodium phosphate salt).	E	4
☐ Goserelin	Dose form: Implant 3.6 mg	E	4
hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial.	E	4
methylprednisolone	Injection: 40 mg/ mL (as sodium succinate) in 1- mL single-dose vial and 5- mL multi-dose vials; 80 mg/ mL (as sodium succinate) in 1- mL single-dose vial.	E	4
☐ prednisolone	Tablet: 5 mg; 20 mg.	E	4
Tamoxifen	Tablet: 10 mg; 20 mg (as citrate).	E	4
9. ANTIPARKINSONISM MEDICINES			
☐ biperiden	Injection: 5 mg (lactate) in 1- mL ampoule.	E	3
	Tablet: 2 mg (hydrochloride).	E	3
levodopa + ☐ carbidopa	Tablet: 250 mg + 25 mg	E	3
10. MEDICINES AFFECTING THE BLOOD			

10.1 Antianaemia medicines			
ferrous salt	Oral liquid: equivalent to 25 mg iron (as sulfate)/ mL.	E	1
	Tablet: equivalent to 60 mg iron.	E	1
ferrous salt + folic acid	Tablet: equivalent to 60 mg iron + 400 micrograms folic acid (nutritional supplement for use during pregnancy).	E	1
Human Recombinant Erythropoietin	20 000IU/ 0.5 mL; 40 000IU/ 1 mL	V	7
folic acid	Tablet: 400 micrograms; 1 mg; 5 mg.	E	1
hydroxocobalamin	Injection: 1 mg (as acetate, as hydrochloride or as sulfate) in 1- mL ampoule.	E	1
10.2 Medicines affecting coagulation			
□ enoxaparin	Injection: ampoule or pre-filled syringe		
	20 mg/0.2 mL; 40 mg/0.4 mL; 60 mg/0.6 mL; 80 mg/0.8 mL; 100 mg/1 mL; 120 mg/0.8 mL; 150 mg/1 mL	V	4
heparin sodium	Injection: 1000 IU/ mL; 5000 IU/ mL; 20 000 IU/ mL in 1- mL ampoule.	V	4
phytomenadione	Injection: 1 mg/ mL; 10 mg/ mL in 5- mL ampoule.	V	4
	Tablet: 10 mg.	V	4
protamine sulfate	Injection: 10 mg/ mL in 5- mL ampoule.	V	4
tranexamic acid	Injection: 100 mg/ mL in 10- mL ampoule.	N	4
□ warfarin	Tablet: 1 mg; 3 mg; 5 mg (sodium salt).	V	4
11. BLOOD PRODUCTS OF HUMAN ORIGIN AND PLASMA SUBSTITUTES			
11.2 Plasma-derived medicines			
11.2.1 Human immunoglobulins			
anti-D immunoglobulin	Injection: 250 micrograms in single-dose vial.	V	7
Anti-rabies	Injection: 150 IU/ mL in vial.	V	7

immunoglobulin			
Anti-tetanus immunoglobulin			
11.2.2 Blood coagulation factors			
coagulation factor IX	Powder for injection: 500 IU/vial, 1000 IU/vial.	V	7
coagulation factor VIII	Powder for injection: 500 IU/vial.	V	7
11.3 Plasma substitutes			
dextran 70	Injectable solution: 6%.		
Albumin (human)	Injectable solution: 20% in 50 mL vial.	V	5
12. CARDIOVASCULAR MEDICINES			
12.1 Antianginal medicines			
☐ bisoprolol	Tablet: 2.5 mg; 5 mg.	E	3
glyceryl trinitrate	Tablet (sublingual): 500 micrograms	V	1
glyceryl trinitrate	Injection for IV infusion: 1 mg/mL	V	3
glyceryl trinitrate	Capsule (XR): 2.5 mg	E	3
☐ isosorbide dinitrate	Tablet: 10 mg, 20 mg.	E	3
verapamil	Tablet: 40 mg; 80 mg (hydrochloride).	N	3
12.2 Antiarrhythmic medicines			
☐ amiodarone	Injection: 50 mg/ mL in 3- mL ampoule (hydrochloride).	N	7
	Tablet: 100 mg; 200 mg; 400 mg (hydrochloride).	N	7
☐ bisoprolol	Tablet: 2.5 mg; 5 mg.	N	3
digoxin	Injection: 250 micrograms/ mL in 2- mL ampoule.	V	7
	Oral liquid: 50 micrograms/ mL.	V	7
	Tablet: 62.5 micrograms; 250 micrograms.	V	7
epinephrine (adrenaline)	Injection: 100 micrograms/ mL (as acid tartrate or hydrochloride) in 10- mL ampoule.	V	3
lidocaine	Injection: 20 mg (hydrochloride)/ mL in 5- mL ampoule.	E	2

verapamil	Injection: 2.5 mg (hydrochloride)/ mL in 2-mL ampoule.	N	7
	Tablet: 40 mg; 80 mg (hydrochloride).	N	7
adenosine	Injection: 6 mg/2ml ampule.	E	6
propafenone	Tablet: 150 mg.	V	7
flecainide	Tablet: 50 mg & 100 mg.	E	7
12.3 Antihypertensive medicines			
□ amlodipine	Tablet: 5 mg (as maleate, mesylate or besylate).	N	6
□ bisoprolol	Tablet: 2.5 mg; 5 mg.	N	6
□ enalapril	Tablet: 2.5 mg; 5 mg (as hydrogen maleate).	N	6
captopril	Tablet (scored): 25 mg.	N	6
magnesium sulphate	Injection: 500 mg/mL	N	6
hydralazine	Powder for injection: 20 mg (hydrochloride) in ampoule.	V	6
	Tablet: 25 mg; 50 mg (hydrochloride).	N	6
□ hydrochlorothiazide	Oral liquid: 50 mg/5 mL.	N	6
	Solid oral dosage form: 12.5 mg; 25 mg.	N	6
methyldopa	Tablet: 250 mg & 500 mg.	V	2
losartan	Tablet: 25 mg, 50 mg & 100 mg.	E	6
Nifedipine (slow release formulations ONLY)	Tablet (slow release): 30 mg	E	6
propranolol	Tablet: 10 mg & Tablet (scored): 40 mg.	V	6
	Injection: 1 mg/mL in 1 mL ampule.	V	3
spironolactone	Tablet: 25 mg & 100mg.	V	4
sodium nitroprusside	Powder for infusion: 50 mg in ampule.	V	4
12.4 Medicines used in heart failure			
□ bisoprolol	Tablet: 2.5 mg; 5 mg.	E	6
digoxin	Injection: 250 micrograms/ mL in 2- mL ampule.	V	7

	Oral liquid: 50 micrograms/ mL.	V	7
	Tablet: 62.5 micrograms; 250 micrograms.	V	7
☐ enalapril	Tablet: 2.5 mg; 5 mg (as hydrogen maleate).	E	3
☐ furosemide	Injection: 10 mg/ mL in 2- mL ampoule.	V	2
	Oral liquid: 20 mg/5 mL.	V	2
	Tablet: 40 mg.	V	2
☐ hydrochlorothiazide	Oral liquid: 50 mg/5 mL.	N	3
	Solid oral dosage form: 25 mg.	N	3
☐ candesartan	Tablet: 8 mg & 16 mg.	N	3
spironolactone	Tablet: 25 mg.	V	7
dopamine	Injection: 40 mg/ mL (hydrochloride) in 5- mL vial.	V	7
dobutamine sulphate	Injection: 2 mg/mL.	V	7
epinephrine	Injection: 1 mg/mL in 1 mL ampule.	V	2
12.5 Antithrombotic medicines			
12.5.1 Anti-platelet medicines			
acetylsalicylic acid	Tablet: 75 mg.	E	1
clopidogrel	Tablet: 75 mg.	V	7
Tirofiban	Injection: 50 microgram/mL & 250 microgram/mL.	V	7
Streptokinase	Powder for injection: 1.5 million IU in vial.	V	7
12.5.2 Thrombolytic medicines			
Alteplase	Powder and solvent for solution for injection: 50 mg & 100 mg vials	V	7
12.6 Lipid-lowering agents			
☐ atorvastatin	Tablet: 20 mg; 40 mg.	E	3
☐ Fenofibrate	Tablet: 160 mg & 200 mg.	E	3
13. DERMATOLOGICAL MEDICINES (topical)			
13.1 Antifungal medicines			

☐ miconazole	Cream: 2% (nitrate) in 20 gm tube.	N	2
selenium sulfide	Detergent-based suspension: 2%.	N	2
benzoic acid + salicylic acid	Ointment: 6% & 3% in 15-30 gram tube.	N	1
13.2 Anti-infective medicines			
fusidic acid	cream 2% in 15-30 gram tube.	N	2
potassium permanganate	Aqueous solution: 1:10 000.	N	1
silver sulfadiazine	Cream: 1%.	E	3
13.3 Anti-inflammatory and antipruritic medicines			
☐ betamethasone	Cream or ointment: 0.1% (as valerate).	E	3
clobetasone propionate	ointment 0.5%	N	2
☐ calamine	Lotion: 5% in 100 mL bottle.	N	1
☐ hydrocortisone	Cream or ointment: 1% (acetate).	N	2
13.4 Medicines affecting skin differentiation and proliferation			
benzoyl peroxide	Cream or lotion: 5%.	E	5
coal tar	Solution: 5%.	E	5
fluorouracil	Ointment: 5%.	E	5
☐ podophyllum resin	Solution: 10% to 25%.	E	5
salicylic acid	Solution: 5%.	E	5
13.5 Scabicides and pediculicides			
☐ benzyl benzoate	Lotion: 25%.	N	1
permethrin	Cream: 5% & Lotion: 1%.	N	2
14. DIAGNOSTIC AGENTS			
14.1 Ophthalmic medicines			

fluorescein	Eye drops: 1% (sodium salt).	E	4
☐ tropicamide	Eye drops: 0.5%.	E	4
14.2 Radiocontrast media			
☐ amidotrizoate	Injection: 140 mg to 420 mg iodine (as sodium or meglumine salt)/ mL in 20- mL ampoule.	N	4
barium sulfate	Aqueous suspension.	N	4
☐ iohexol	Injection: 140 mg to 350 mg iodine/ mL in 5- mL; 10- mL; 20- mL ampoules.	N	4
☐ meglumine iotroxate	Solution: 5 g to 8 g iodine in 100 mL to 250 mL.	N	4
15. DISINFECTANTS AND ANTISEPTICS			
15.1 Antiseptics			
☐ chlorhexidine	Solution: 5% (digluconate).	N	1
☐ ethanol	Solution: 70% (denatured).	E	1
☐ povidone iodine	Solution: 10% (equivalent to 1% available iodine).	E	1
15.2 Disinfectants			
alcohol based hand rub	Solution: containing ethanol 80% volume /volume	E	1
	Solution: containing isopropyl alcohol 75% volume/volume	E	1
☐ chlorine base compound	Powder: (0.1% available chlorine) for solution.	E	2
☐ chloroxylenol	Solution: 4.8%.		
Glutaral	Solution: 2%.		
16. DIURETICS			
☐ furosemide	Injection: 10 mg/ mL in 2- mL ampoule.	V	2
	Oral liquid: 20 mg/5 mL.	V	2
	Tablet: 10 mg; 20 mg; 40 mg.	V	2
☐ hydrochlorothiazide	Solid oral dosage form: 25 mg.	E	6

mannitol	Injectable solution: 10%; 20%.	V	3
spironolactone	Tablet: 100 mg.	V	3
17. GASTROINTESTINAL MEDICINES			
☐ pancreatic enzymes	Age-appropriate formulations and doses including lipase, protease and amylase.	E	3
17.1 Antiulcer medicines			
☐ omeprazole	Powder for injection: 40 mg in vial	E	3
	Solid oral dosage form: 10 mg; 20 mg; 40 mg.	E	2
☐ ranitidine	Injection: 25 mg/ mL (as hydrochloride) in 2-mL ampoule.	E	2
	Tablet: 150 mg (as hydrochloride).	N	1
17.2 Antiemetic medicines			
dexamethasone	Injection: 4 mg/ mL in 1- mL ampoule (as disodium phosphate salt).	V	2
	Oral liquid: 0.5 mg/5 mL; 2 mg/5 mL.	E	2
	Solid oral dosage form: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg.	E	2
metoclopramide	Injection: 5 mg (hydrochloride)/ mL in 2- mL ampoule.	V	2
ondansetron	Injection: 2 mg base/ mL in 2- mL ampoule (as hydrochloride).	V	7
	Oral liquid: 4 mg base/5 mL.	V	7
	Solid oral dosage form: Eq 4 mg base; Eq 8 mg base; Eq 24 mg base.	V	7
17.3 Anti-inflammatory medicines			
mesalazine	Suppository: 1000 mg; Tablet: 800 mg.		
☐ sulfasalazine	Retention enema. Suppository: 500 mg.	N	3
	Tablet: 500 mg.	N	3
☐ hydrocortisone	Retention enema.	V	3
	Suppository: 25 mg (acetate).	V	3
methylprednisolone	Injection: 40 mg/mL.	E	3
17.4 Laxatives			
bisacodyl	Tablet (enteric coated): 10 mg.	N	2

Glycerin	Suppository	N	3
17.5 Medicines used in diarrhoea			
17.5.1 Oral rehydration			
oral rehydration salts	Powder for dilution in 200 mL; 500 mL; 1 L. glucose: 75 mEq sodium: 75 mEq or mmol/L chloride: 65 mEq or mmol/L potassium: 20 mEq or mmol/L citrate: 10 mmol/L osmolarity: 245 mOsm/L glucose: 13.5 g/L sodium chloride: 2.6 g/L potassium chloride: 1.5 g/L trisodium citrate dihydrate: 2.9 g/L	V	1
17.5.2 Medicines for diarrhoea			
zinc sulfate	Solid oral dosage form: 20 mg.	V	1
18. HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES			
18.1 Adrenal hormones and synthetic substitutes			
fludrocortisone	Tablet: 100 micrograms (acetate).	V	3
hydrocortisone	Tablet: 5 mg; 10 mg; 20 mg.	V	3
18.2 Androgens			
18.3 Contraceptives			
18.3.1 Oral hormonal contraceptives			
☐ ethinylestradiol + ☐ levonorgestrel	Tablet: 30 micrograms + 150 micrograms.	E	3
☐ ethinylestradiol + ☐ norethisterone	Tablet: 35 micrograms + 1 mg.	E	3
levonorgestrel	Tablet: 750 micrograms (pack of two)	E	3
18.3.2 Injectable hormonal contraceptives			
estradiol cypionate + medroxyprogester	Injection: 5 mg + 25 mg.	E	3

one acetate			
medroxyprogesterone acetate	Injection (intramuscular): 150 mg/ mL in 1- mL vial.	E	3
norethisterone enantate	Oily solution: 200 mg/ mL in 1- mL ampoule.	E	3
18.3.3 Intrauterine devices		E	
copper-containing device		N	2
levonorgestrel-releasing intrauterine system	Intrauterine system with reservoir containing 52 mg of levonorelrel	N	2
18.3.4 Barrier methods			
condoms		N	1
18.3.5 Implantable contraceptives			
levonorgestrel-releasing implant	Two-rod levonorgestrel-releasing implant, each rod containing 75 mg of levonorgestrel (150 mg total).	N	3
18.3.6 Intravaginal contraceptives			
progesterone vaginal ring	Progesterone-releasing vaginal ring containing 2.074 g of micronized progesterone	N	3
18.4 Estrogens			
18.5 Insulins and other medicines used for diabetes			
☐ gliclazide	Solid oral dosage form: (controlled-release tablets) 30 mg; 60 mg; 80 mg.	E	4
glucagon	Injection: 1 mg/ mL.	V	4
insulin injection (soluble)	Injection: 40 IU/ mL in 10- mL vial; 100 IU/ mL in 10- mL vial.	V	4
		V	4
intermediate-acting insulin	Injection: 40 IU/ mL in 10- mL vial; 100 IU/ mL in 10- mL vial (as compound insulin zinc suspension or isophane insulin).	V	4
Insulin Mixtard (30\70) (50\50)	Injection 100 IU\ML Vial,10ml	V	4
metformin	Tablet: 500 mg (hydrochloride).	E	4
18.6 Ovulation inducers			
clomifene	Tablet: 50 mg (citrate).	E	5

18.7 Progestogens			
☐ norethindrone	Tablet: 5 mg.	E	3
☐ medroxyprogesterone acetate	Tablet: 5 mg.	E	3
18.8 Thyroid hormones and antithyroid medicines			
levothyroxine	Tablet: 25 micrograms; 50 micrograms; 100 micrograms (sodium salt).	V	3
potassium iodide	Tablet: 60 mg.	V	3
☐ propylthiouracil	Tablet: 50 mg.	V	3
☐ Carbimazole	Tablet: 5 mg.	V	3
19. IMMUNOLOGICALS			
19.1 Diagnostic agents			
tuberculin, purified protein derivative (PPD)	Injection.	E	5
19.2 Sera and immunoglobulins			
Anti-venom immunoglobulin	Injection.	V	5
	Exact type to be defined locally.	V	5
diphtheria antitoxin	Injection: 10 000 IU; 20 000 IU in vial.	N	5
19.3 Vaccines			
Recommendations for all			
BCG vaccine		V	1
hepatitis B vaccine		V	1
pneumococcal vaccine		V	1
poliomyelitis vaccine		V	1
rotavirus vaccine		V	1
bivalent oral polio vaccine (BOPV)		V	1
penta vaccine		V	1
measles and rubella vaccine		V	1
injection polio vaccine (IPV)		V	1

tetanus and diphtheria vaccine (TD)		V	1
Recommendations for some high-risk populations			
cholera vaccine		V	1
meningococcal meningitis vaccine		V	1
rabies vaccine		V	1
typhoid vaccine		V	1
Recommendations for immunization programmes with certain characteristics			
influenza vaccine (seasonal)		E	1
20. MUSCLE RELAXANTS (PERIPHERALLY-ACTING) AND CHOLINESTERASE INHIBITORS			
☐ atracurium	Injection: 10 mg/ mL (besylate).	V	1
suxamethonium	Injection: 50 mg (chloride)/ mL in 2- mL ampoule.	V	1
	Powder for injection (chloride), in vial.	V	1
☐ vecuronium	Powder for injection: 10 mg (bromide) in vial.	V	1
21. OPHTHALMOLOGICAL PREPARATIONS			
21.1 Anti-infective agents			
aciclovir	Ointment: 3% W/W.	N	3
☐ erythromycin	Ointment: 0.5%, drops:	N	3
☐ gentamicin	Solution (eye drops): 0.3% (sulfate).	N	3
o tetracycline		V	1
21.2 Anti-inflammatory agents			
☐ prednisolone	Solution (eye drops): 0.5% (sodium phosphate).	N	3
21.3 Local anaesthetics			
☐ tetracaine	Solution (eye drops): 0.5% (hydrochloride).	N	3
21.4 Miotics and antiglaucoma medicines			
acetazolamide	Tablet: 250 mg.	N	3
latanoprost	Solution (eye drops): latanoprost 50	E	3

	micrograms/mL		
☐ pilocarpine	Solution (eye drops): 2%; 4% (hydrochloride or nitrate).	E	3
☐ timolol	Solution (eye drops): 0.25%; 0.5% (as hydrogen maleate).	N	3
22. OXYTOCICS AND ANTIOXYTOCICS			
22.1 Oxytocics			
☐ ergometrine	Injection: 200 micrograms (hydrogen maleate) in 1- mL ampoule.	E	3
misoprostol	Tablet: 200 micrograms.	E	3
	Vaginal tablet: 25 micrograms.	E	3
oxytocin	Injection: 10 IU in 1- mL.	E	3
22.2 Antioxytocics (tocolytics)			
Magnesium Sulphate	IV Infusion: 1g in 500 mL.	E	3
23. PERITONEAL DIALYSIS SOLUTION			
intraperitoneal dialysis solution (of appropriate composition)	Parenteral solution.	V	7
24. MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS			
24.1 Medicines used in psychotic disorders			
☐ chlorpromazine	Tablet: 50 mg; 100 mg (hydrochloride).	V	5
☐ haloperidol	Injection: 5 mg in 1- mL ampoule.	V	5
	Tablet: 0.5 mg; 1.5 mg; 10 mg.	V	5
☐ haloperidol decanoate	Injection: 50 mg & 100 mg.	V	5
risperidone	Solid oral dosage form: 2 mg; 3 mg.	E	5
clozapine	Solid oral dosage form: 25 mg; 100 mg.	E	3
24.2 Medicines used in mood disorders			
24.2.1 Medicines used in depressive disorders			
☐ amitriptyline	Tablet: 25 mg; 75mg. (hydrochloride).	E	5
fluoxetine	Solid oral dosage form: 20 mg (as hydrochloride).	E	5
24.2.2 Medicines used in bipolar disorders			

carbamazepine	Tablet (scored): 100 mg; CR tablet: 200 mg & 400 mg.	V	5
lithium carbonate	Solid oral dosage form: 300 mg. CR tablet: 400 mg.	V	3
valproic acid (sodium valproate)	Tablet (enteric-coated): 200 mg; 500 mg (sodium valproate). Oral liquid: 250 mg/5ml.	E	5
24.3 Medicines for anxiety disorders			
☐ diazepam	Tablet (scored): 2 mg; 5 mg.	E	3
24.4 Medicines used for obsessive compulsive disorders			
clomipramine	Capsule: 10 mg; 25 mg (hydrochloride).	E	3
24.5 Medicines for disorders due to psychoactive substance use			
nicotine replacement therapy (NRT)	Chewing gum: 2 mg; 4 mg (as polacrilex).	N	
	Transdermal patch: 5 mg to 30 mg/16 hrs; 7 mg to 21 mg/24 hrs.	N	
☐ methadone	Concentrate for oral liquid: 5 mg/ mL; 10 mg/ mL (hydrochloride).	V	
	Oral liquid: 5 mg/5 mL; 10 mg/5 mL (hydrochloride).	V	
25. MEDICINES ACTING ON THE RESPIRATORY TRACT			
25.1 Antiasthmatic and medicines for chronic obstructive pulmonary disease			
☐ beclometasone	Inhalation (aerosol): 50 micrograms (dipropionate) per dose; 100 micrograms (dipropionate) per dose (as CFC free forms).	E	3
☐ budesonide + formoterol	Dry powder inhaler: 100 micrograms + 6 micrograms per dose; 200 micrograms + 6 micrograms per dose	E	3
epinephrine (adrenaline)	Injection: 1 mg (as hydrochloride or hydrogen tartrate) in 1- mL ampoule.	V	3
ipratropium bromide	Inhalation (aerosol): 20 micrograms/metered dose.	V	3
☐ salbutamol	Inhalation (aerosol): 100 micrograms (as sulfate) per dose.	V	3
	Injection: 50 micrograms (as sulfate)/ mL in 5- mL ampoule.	V	3
	Metered dose inhaler (aerosol): 100 micrograms (as sulfate) per dose.	V	3

	Respirator solution for use in nebulizers: 5 mg (as sulfate)/ mL.	V	3
26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES			
26.1 Oral			
oral rehydration salts	Powder for dilution in 200 mL; 500 mL; 1 L. glucose: 75 mEq sodium: 75 mEq or mmol/L chloride: 65 mEq or mmol/L potassium: 20 mEq or mmol/L citrate: 10 mmol/L osmolarity: 245 mOsm/L glucose: 13.5 g/L sodium chloride: 2.6 g/L potassium chloride: 1.5 g/L trisodium citrate dihydrate: 2.9 g/L.	V	2
potassium chloride	Powder for solution.	V	7
26.2 Parenteral			
glucose	Injectable solution: 5% (isotonic); 10% (hypertonic); 50% (hypertonic).	V	1
glucose with sodium chloride	Injectable solution: 4% glucose, 0.18% sodium chloride (equivalent to Na ⁺ 30 mmol/L, Cl ⁻ 30 mmol/L).	V	1
	Injectable solution: 5% glucose, 0.9% sodium chloride (equivalent to Na ⁺ 150 mmol/L and Cl ⁻ 150 mmol/L); 5% glucose, 0.45% sodium chloride (equivalent to Na ⁺ 75 mmol/L and Cl ⁻ 75 mmol/L).	V	1
potassium chloride	Solution: 11.2% in 20- mL ampoule	V	7
	(equivalent to K ⁺ 1.5 mmol/ mL, Cl ⁻ 1.5 mmol/ mL).		
	Solution for dilution: 7.5% (equivalent to K 1 mmol/ mL and Cl 1 mmol/ mL); 15% (equivalent to K 2 mmol/ mL and Cl		

	2 mmol/ mL).		
sodium chloride	Injectable solution: 0.9% isotonic (equivalent to Na ⁺ 154 mmol/L, Cl ⁻ 154 mmol/L).	V	1
sodium hydrogen carbonate	Injectable solution: 1.4% isotonic (equivalent to Na ⁺ 167 mmol/L, HCO ₃ ⁻ 167 mmol/L).	E	3
	Solution: 8.4% in 10- mL ampoule (equivalent to Na ⁺ 1000 mmol/L, HCO ₃ ⁻ 1000 mmol/L).	E	3
o Ringer lactate solution	Injectable solution.	V	1
26.3 Miscellaneous			
water for injection	2- mL; 5- mL; 10- mL ampoules.	V	1
27. VITAMINS AND MINERALS			
ascorbic acid	Tablet: 50 mg.	N	1
calcium	Tablet: 500 mg (elemental).	N	1
colecalfiferol	Oral liquid: 400 IU/ mL.	N	1
	Solid oral dosage form: 400 IU; 1000 IU.	N	1
□ ergocalciferol	Oral liquid: 250 micrograms/ mL (10 000 IU/ mL).	N	1
	Solid oral dosage form: 1.25 mg (50 000 IU).	N	1
iodine	Capsule: 200 mg.	N	1
	Iodized oil: 1 mL (480 mg iodine); 0.5 mL (240 mg iodine) in ampoule (oral or injectable); 0.57 mL (308 mg iodine) in dispenser bottle.	N	1
□ nicotinamide	Tablet: 50 mg.	N	1
pyridoxine	Tablet: 25 mg (hydrochloride).	N	1
retinol	Capsule: 50 000 IU; 100 000 IU; 200 000 IU (as palmitate).	N	1
	Oral oily solution: 100 000 IU (as palmitate)/ mL in multidose dispenser.	N	1
	Tablet (sugar-coated): 10 000 IU (as palmitate).	N	1
	Water-miscible injection: 100 000 IU (as	N	1

	palmitate) in 2- mL ampoule.		
riboflavin	Tablet: 5 mg.	N	1
sodium fluoride	In any appropriate topical formulation.	N	1
thiamine	Tablet: 50 mg (hydrochloride).	N	1
28. EAR, NOSE AND THROAT MEDICINES			
acetic acid	Topical: 2%, in alcohol.	E	3
☐ budesonide	Nasal spray: 100 micrograms per dose.	E	3
☐ ciprofloxacin	Topical: 0.3% drops (as hydrochloride).	E	3
☐ xylometazoline	Nasal spray: 0.05%.	E	3
29. SPECIFIC MEDICINES FOR NEONATAL CARE			
29.1 Medicines administered to the neonate			
caffeine citrate	Injection: 20 mg/ mL (equivalent to 10 mg caffeine base/ mL).	V	3
	Oral liquid: 20 mg/ mL (equivalent to 10 mg caffeine base/ mL).	V	3
chlorhexidine	Solution or gel: 7.1% (digluconate) delivering 4% chlorhexidine (for umbilical cord care).	N	3
☐ ibuprofen	Solution for injection: 5 mg/ mL.	E	3
☐ prostaglandin E	Solution for injection:	V	3
	Prostaglandin E1: 0.5 mg/ mL in alcohol.	V	3
	Prostaglandin E 2: 1 mg/ mL.	V	3
surfactant	Suspension for intratracheal instillation: 25 mg/ mL or 80 mg/mL.	E	3
29.2 Medicines administered to the mother			
Dexamethasone	Injection: 4 mg/ mL dexamethasone phosphate (as disodium salt).	E	3
30. MEDICINES FOR DISEASES OF JOINTS			
30.1 Medicines used to treat gout			
allopurinol	Tablet: 100 mg.	E	3
30.2 Disease-modifying agents used in rheumatoid disorders (DMARDs)			
hydroxychloroquine	Solid oral dosage form: 200 mg (assulfate).	V	4
methotrexate	Tablet: 2.5 mg (as sodium salt).	V	4
sulfasalazine	Tablet: 500 mg.	V	4

Table 1.1: Medicines with age or weight restrictions

artesunate + pyronaridine tetraphosphate	> 5 kg
atazanavir	>25 kg
atropine	>3 months
benzyl benzoate	>2 years
betamethasone topical preparations	hydrocortisone preferred in neonates
cefazolin	>1 month
ceftriaxone	>41 weeks corrected gestational age
darunavir	> 3 years
delamanid	> 6 years
dihydroartemisinin + piperaquine phosphate	> 5 kg
diloxanide	>25 kg
doxycycline	>8 years (except for serious infections e.g. cholera)
efavirenz	>3 years or >10 kg
fluoxetine	>8 years
ibuprofen	>3 months (except IV form for patent ductus arteriosus)
mefloquine	>5 kg or >3 months
metoclopramide	Not in neonates
nevirapine	> 6 weeks
ondansetron	>1 month
silver sulfadiazine	>2 months
tetracaine	Not in preterm neonates
trimethoprim	>6 months
xylometazoline	>3 months

Table 1.2: Explanation of dosage forms

A. Principal dosage forms used in EML – oral administration Term	Definition
Solid oral dosage form	Refers to tablets or capsules or other solid dosage forms such as 'melts' that are immediate-release preparations. It implies that there is no difference in clinical efficacy or safety between the available dosage forms, and countries should therefore choose the form(s) to be listed depending on quality and availability. The term 'solid oral dosage form' is <i>never</i> intended to allow any type of modified-release tablet.
Tablets	Refers to: ☐ uncoated or coated (film-coated or sugar-coated) tablets that are intended to be swallowed whole; ☐ unscored and scored*; ☐ tablets that are intended to be chewed before being swallowed; ☐ tablets that are intended to be dispersed or dissolved in water or another suitable liquid before being swallowed; ☐ tablets that are intended to be crushed before being swallowed. The term 'tablet' without qualification is <i>never</i> intended to allow any type of modified-release tablet.
Tablets (qualified)	Refers to a specific type of tablet: chewable - tablets that are intended to be chewed before being swallowed; dispersible - tablets that are intended to be dispersed in water or another suitable liquid before being swallowed; soluble - tablets that are intended to be dissolved in water or another suitable liquid before being swallowed; crushable - tablets that are intended to be crushed before being swallowed; scored - tablets bearing a break mark or marks where sub-division is intended in order to provide doses of less than one tablet;

A. Principal dosage forms used in EML – oral administration Term	Definition
	sublingual - tablets that are intended to be placed beneath the tongue. The term 'tablet' is <i>always</i> qualified with an additional term (in parentheses) in entries where one of the following types of tablet is intended: gastro-resistant (such tablets may sometimes be described as enteric-coated or as delayed-release), prolonged-release or another modified-release form.
Capsules	Refers to hard or soft capsules. The term 'capsule' without qualification is never intended to allow any type of modified-release capsule.
Capsules (qualified)	The term 'capsule' with qualification refers to gastro-resistant (such capsules may sometimes be described as enteric-coated or as delayed-release), prolonged-release or another modified-release form.
Granules	Preparations that are issued to patient as granules to be swallowed without further preparation, to be chewed, or to be taken in or with water or another suitable liquid. The term 'granules' without further qualification is never intended to allow any type of modified-release granules.
Oral powder	Preparations that are issued to patient as powder (usually as single-dose) to be taken in or with water or another suitable liquid.
Oral liquid	Liquid preparations intended to be swallowed i.e. oral solutions, suspensions, emulsions and oral drops, including those constituted from powders or granules, but not those preparations intended for oromucosal administration e.g. gargles and mouthwashes. Oral liquids presented as powders or granules may offer benefits in the form of better stability and lower transport costs. If more than one type of oral liquid is available on the same market (e.g. solution, suspension, granules for reconstitution), they may be interchanged and in such cases should be bioequivalent. It is preferable that oral liquids do not contain sugar and that solutions for children do not contain alcohol.